{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:50:14Z","timestamp":1791237014978,"version":"4.1.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Detecting resistance to fluoroquinolones (FQ) and second-line injectable drugs (amikacin [AMK], kanamycin [KAN], and capreomycin [CAP]) is crucial given the worldwide increase in the incidence of extensively drug-resistant tuberculosis (XDR-TB). A new version of the GenoType MTBDR\n            <jats:italic>sl<\/jats:italic>\n            test (v2.0) has been developed to improve the detection of resistance to FQ (involving\n            <jats:italic>gyrA<\/jats:italic>\n            and\n            <jats:italic>gyrB<\/jats:italic>\n            mutations) and to second-line injectable drugs (involving\n            <jats:italic>rrs<\/jats:italic>\n            and\n            <jats:italic>eis<\/jats:italic>\n            promoter mutations) in\n            <jats:named-content content-type=\"genus-species\">Mycobacterium tuberculosis<\/jats:named-content>\n            . A collection of 127 multidrug-resistant (MDR)\n            <jats:named-content content-type=\"genus-species\">M. tuberculosis<\/jats:named-content>\n            complex strains was tested using the first (v1) and second (v2.0) versions of the MTBDR\n            <jats:italic>sl<\/jats:italic>\n            test, as well as DNA sequencing. The specificities in resistance detection of v1 and v2.0 were similar throughout, whereas the levels of sensitivity of v2.0 were superior for FQ (94.8% versus 89.6%) and KAN (90.5% versus 59.5%) but similar for AMK (91.3%) and CAP (83.0%). The sensitivity and specificity of v2.0 were superior to those of v1 for the detection of pre-XDR strains (83.3% versus 75.0% and 88.6% versus 67.1%, respectively), whereas the sensitivity of v2.0 was superior to that of v1 only for the detection of XDR strains (83.0% versus 49.1%). In conclusion, MTBDR\n            <jats:italic>sl<\/jats:italic>\n            v2.0 is superior to MTBDR\n            <jats:italic>sl<\/jats:italic>\n            v1 and efficiently detects the most common mutations involved in resistance to FQ and aminoglycosides\/CAP. However, due to mutations not recognized by v2.0 or to the presence of resistance mechanisms not yet characterized (particularly mechanisms related to monoresistance to aminoglycosides or CAP), the results for wild-type strains obtained with MTBDR\n            <jats:italic>sl<\/jats:italic>\n            v2.0 should be confirmed by further DNA sequencing and phenotypic drug susceptibility testing.\n          <\/jats:p>","DOI":"10.1128\/jcm.00051-16","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T05:24:16Z","timestamp":1460006656000},"page":"1573-1580","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":51,"title":["Performance of the New Version (v2.0) of the GenoType MTBDR\n            <i>sl<\/i>\n            Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains"],"prefix":"10.1128","volume":"54","author":[{"given":"Florence","family":"Brossier","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Universit\u00e9 Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux (NRC MyrMA), Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Guindo","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Universit\u00e9 Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Universit\u00e9 Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Reibel","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Universit\u00e9 Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux (NRC MyrMA), Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladimir","family":"Sougakoff","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Universit\u00e9 Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux (NRC MyrMA), Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Universit\u00e9 Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux (NRC MyrMA), Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Aubry","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Universit\u00e9 Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux (NRC MyrMA), Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"WHO\/HTM\/TB\/2015.22","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Global tuberculosis report 2015. WHO\/HTM\/TB\/2015.22. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","volume-title":"WHO HTM\/TB\/2008.402","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO HTM\/TB\/2008.402. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00155708"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr566"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06272-11"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3192-3197.2005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02059-14"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks178"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907925106"},{"key":"e_1_3_2_11_2","volume-title":"WHO\/HTM\/TB\/2013.01","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. 2013. Expert group meeting report: the use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. WHO\/HTM\/TB\/2013.01. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055292"},{"key":"e_1_3_2_13_2","first-page":"217","article-title":"Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation","volume":"27","author":"Canetti G","year":"1963","unstructured":"Canetti G, Rist N, Grosset J. 1963. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. Rev Tuberc Pneumol (Paris) 27:217\u2013272. (In French.)","journal-title":"Rev Tuberc Pneumol (Paris)"},{"key":"e_1_3_2_14_2","volume-title":"WHO\/HTM\/TB\/2008.392","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO\/HTM\/TB\/2008.392. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_15_2","volume-title":"GenoType MTBDRsl Ver2.0: instruction manual","author":"Hain Lifescience GmbH","year":"2015","unstructured":"Hain Lifescience GmbH. 2015. GenoType MTBDRsl Ver2.0: instruction manual. Hain Lifescience GmbH, Nehren, Germany."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01947-09"},{"key":"e_1_3_2_17_2","unstructured":"Dean AG Sullivan KM Soe MM. 2014. OpenEpi: open source epidemiologic statistics for public health version 3.03. www.OpenEpi.com. Updated 22 September 2014."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-148-10-2967"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00150-15"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010705.pub2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01257-15"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04058-14"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039754"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095083"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00287-09"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-10"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr109"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00857-13"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.571-577.2005"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02191-12"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.06.031"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033275"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00506-13"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00968-10"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00553-13"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00051-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00051-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T08:52:39Z","timestamp":1646470359000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00051-16"}},"subtitle":[],"editor":[{"given":"G. A.","family":"Land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1128\/JCM.00051-16"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00051-16","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"2016-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}